Emerging Artificial Intelligence Technologies for Risk Assessment and Management in Acute Myeloid Leukemia

AI technologies hold potential to improve AML treatment through enhanced risk stratification, early detection capabilities, and individualized treatment optimization. The transition toward explainable AI models is essential to clinical readiness, with federated learning architectures resolving data scarcity concerns. Seamless integration requires harmonized data standards, robust regulatory frameworks, and equitable access to technology to fully realize the transformative potential of AI in improving outcomes for patients with AML globally.

Corresponding Author: Huasheng Liu, MD, PhD, Department of Hematology, The First Affiliated Hospital of Xi’an Jiaotong University, 277 W Yanta Rd, Xi’an, Shaanxi, PR China (lhs681995@126.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.